In vitro susceptibility of gram-negative bacilli from pediatric patients to moxalactam, cefotaxime, Ro 13-9904, and other cephalosporins.
Moxalactam, Ro 13-9904, cefotaxime, cefoperazone, older cephalosporins, and four aminoglycosides were tested in vitro against 432 strains of gram-negative bacteria isolated from pediatric patients. The new drugs were uniformly active against coliform bacilli obtained from patients with meningitis and against aminoglycoside-resistant coliform bacilli.
D001419:Bacteria / Q000187:drug effects*; D001424:Bacterial Infections / Q000382:microbiology; D002439:Cefotaxime; D002443:Ceftriaxone; D002511:Cephalosporins / Q000494:pharmacology; D002513:Cephamycins / Q000494:pharmacology; D002648:Child; D004352:Drug Resistance, Microbial; D006801:Humans; D009070:Moxalactam
D002511:Cephalosporins; D002513:Cephamycins; D002443:Ceftriaxone; D002439:Cefotaxime; D009070:Moxalactam